Abstract
Myo-inositol (MI) has known to exert anti-diabetic, anti-oxidative and anti-inflammatory properties. The present study examined the effects of MI supplementation on the expression of some inflammatory genes, serum high-sensitivity C-reactive protein (hs-CRP), WBC-derived inflammatory biomarkers, body composition and liver function in obese patients with non-alcoholic fatty liver disease (NAFLD). Forty-eight obese patients with NAFLD were randomly allocated into either MI (4 g/day) or placebo (maltodextrin 4 g/day) group along with dietary recommendations for 8 weeks. At the end of the study, reduction in fat mass and an increase in fat free mass were statistically greater in the MI group compared with placebo group. Moreover, MI supplementation resulted in a significant reduction in TNF-α mRNA expression, compared with placebo. Despite the decrease in systemic inflammation response index (SIRI) and monocytes to lymphocyte ratio (MLR) in the MI group, no differences were observed in other WBC-derived inflammatory markers as well as serum hs-CRP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
